Safety and Immunogenicity of GSK Biologicals' Candidate Tuberculosis Vaccine (692342) When Administered to HIV-positive Adults Living in a Tuberculosis Endemic Region
收藏DataCite Commons2024-12-02 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/00002921/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of the study is to assess the safety and immunogenicity of a GlaxoSmithKline (GSK) Biologicals' candidate tuberculosis vaccine (692342) administered to Human Immunodeficiency Virus (HIV)-positive adults aged 18 to 59 years, living in a tuberculosis endemic region. Subjects will be followed-up for 3 years. Subjects will be enrolled in 3 cohorts: - HIV-positive adults on highly active antiretroviral therapy - HIV-positive adults not on highly active antiretroviral therapy - HIV-negative adults Each cohort will have 2 groups.
提供机构：
Vivli
创建时间：
2018-10-27
